Generated: November 18, 2017
DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 201679
, which is a drug marketed by Elkins Sinn, Sun Pharm Inds, Mylan, Watson Labs, Sandoz, Impax Labs Inc, Nostrum Labs Inc, Ivax Sub Teva Pharms, Amneal Pharms, Actavis Mid Atlantic, Whiteworth Town Plsn, Novel Labs Inc, Actavis Labs Fl Inc, Watson Labs Inc, and Ranbaxy Labs Ltd, and is included in twenty-seven NDAs. It is available from twenty-four suppliers. Additional details are available on the NITROFURANTOIN profile page.
The generic ingredient in NITROFURANTOIN is nitrofurantoin; nitrofurantoin, macrocrystalline. There are twenty drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the nitrofurantoin; nitrofurantoin, macrocrystalline profile page.
Pharmacology for NDA: 201679
Complete Access Available with Subscription
Summary for product number 001
|Approval Date:||May 11, 2011||TE:||AB||RLD:||No|
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.